Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.60 |
| ▸ | EGFR | P00533 | 15/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.57 |
| ▸ | ROS1 | P08922 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.49 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1502181 | 0.87 | EGFR (0.64) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL4534304 | 0.86 | ERBB2 (0.63) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL4560679 | 0.83 | ERBB2 (0.60) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL6769889 | 0.79 | ERBB2 (0.68) | ERBB2EGFRERBB4 | |
| SCHEMBL7004234 | 0.79 | ERBB2 (0.55) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL7886632 | 0.79 | ERBB2 (0.70) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL7888548 | 0.78 | ERBB2 (0.71) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL3320217 | 0.78 | ERBB2 (0.69) | ERBB2EGFRAURKBERBB4CHEK2 | |
| SCHEMBL7004232 | 0.78 | ERBB2 (0.56) | ERBB2EGFRAURKBERBB4CHEK2 | |
| Dimethylamine SCHEMBL6768117 | 0.78 | EGFR (0.59) | ERBB2EGFRAURKBERBB4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169091-B1 | TREATMENT OF PSORIASIS, FIBROSIS, ATHEROSCLEROSIS, RESTENOSIS, AUTO-IMMUNE DISEASE, ALLERGY, ASTHMA | GLAXO WELLCOME INC. | 2001-01-02 | — | — | US | claimed |
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-6169091-B1 | TREATMENT OF PSORIASIS, FIBROSIS, ATHEROSCLEROSIS, RESTENOSIS, AUTO-IMMUNE DISEASE, ALLERGY, ASTHMA | GLAXO WELLCOME INC. | 2001-01-02 | — | — | US | disclosed |